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Abstract
Background: With the exception of sexual functioning and weight, social and behavioural effects
of postmenopausal hormone therapy (HT) have not been reported from trials. This paper reports
such results from the EPHT-trial in Estonia.
Methods: A randomized trial, with a blind and non-blind sub-trial in Estonia. From 1999–2001,
1778 women were recruited. The mean follow-up was 3.6 years. Women's experiences were asked
in the first and final study year by mailed questionnaires (74 and 81% response rates). Comparisons
of the groups were made by cross-tabulation and logistic regression, adjusting for age.
Results: There were no differences between the HT and non-HT groups in regard to being
employed, the extent of social involvement or marital status or opinions on aging. There was no
difference in the frequency of free-time exercise, or overweight. Some of the indicators suggested
less sexual inactivity, but the differences were small.
Conclusion: In a trial setting, postmenopausal hormone therapy did not influence work or social
involvement or health behaviour.
Trial registration: ISRCTN35338757
Background
The health effects on diseases, symptoms and well-being
of postmenopausal hormone therapy (HT) have been a
focus of research for good reason. In lay-thinking HT is
often perceived to lead to better work and social capacity
and family harmony [1,2]. With the exception of sexual
functioning and weight (as a proxy for health habits),
non-health benefits, such as better work capacity and
social involvement have not been studied in trials, devoid
of selection bias, and the data of surveys are also limited.
Surveys of both physicians and women have focused on
the level of HT use and the medical reasons for use; non-
Published: 8 June 2009
BMC Women's Health 2009, 9:16 doi:10.1186/1472-6874-9-16
Received: 5 January 2009
Accepted: 8 June 2009
This article is available from: http://www.biomedcentral.com/1472-6874/9/16
© 2009 Hemminki et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Women's Health 2009, 9:16 http://www.biomedcentral.com/1472-6874/9/16
Page 2 of 9
(page number not for citation purposes)
medical reasons have been rarely asked. When it has been
asked, some physicians [3-7] and women [5,8-17] report
they prescribe or use HT to improve sexual functioning or
to delay aging, or at least they believe it would.
In addition to studying the effects of HT on health and
health services in our trial in Estonia [18], we also wanted
to study the effects on work, social activities, partner rela-
tionships, sexual life and physical activity, as well as on
women's views on aging. This information was asked in
annually mailed questionnaires. We report cross-sectional
comparisons of the treatment groups on the first year and
last year, because these surveys contained most of the rel-
evant questions to this study.
Methods
Postmenopausal women aged 50–64 and living in Tallinn
(the capital of Estonia), Tartu, and in two counties sur-
rounding these towns were asked to participate in a post-
menopausal hormone therapy trial [18]. Potentially
eligible women were randomized into four trial groups:
1) blind hormone therapy group, 2) blind placebo group,
3) non-blind hormone therapy group, 4) non-treatment
group. Randomization occurred before mailing the invita-
tion for the recruitment visit in order to study the impact
of blinding on recruitment. The non-blind sub-trial was
designed to study the impact of hormone therapy on
health service utilization.
Altogether 1001 women were recruited into the non-blind
sub-trial and 777 in the blind sub-trial at three clinical
centres between January 1999 and December 2001.
Details of the trial design, flow-chart, randomization, eli-
gibility criteria, recruitment, and clinical follow-up of par-
ticipants are described elsewhere [18]. Trial treatment was
stopped by May 2004. The mean follow-up period for trial
participants was 3.6 years. All participants gave written
informed consent. The trial design was approved by the
Tallinn Committee of Medical Ethics and the Research
Ethics Committee of University Clinic of Tampere. The
trial is registered as ISRCTN35338757 (ISRCTN register.
http://isrctn.org/).
All participants were mailed annual questionnaires that
included questions about their working status, weight and
physical exercising, social activities, marital status, and
sexual life. The first year survey and the final survey (filled
in on average 3.6 years (range 2.2–4.9 years) after inclu-
sion into the study) contained the most relevant ques-
tions to this study. The response rates in the surveys were
74 and 81%. There was no difference between the trial
groups in the response rates to annual questionnaires. The
key questions (translated into English) are given in
Appendix 1. Some of them were made for other purposes
than studying the social and behavioural effects. The first-
year questionnaire included an instrument "Women's
Health Questionnaire" [19], with some questions on
aging and sex being relevant to our analyses; they are indi-
cated by the abbreviation WHQ in brackets in the results.
The proportion of women not having a partner was
derived from questions on partner satisfaction or from
questions on importance of sexual life (see Appendix).
Results on adherence and the reasons for non-adherence
have been reported separately [20]. The proportion of
women in the hormone therapy groups who took over
20% of their assigned trial medication was 83% at the end
of the first trial year, and 64% by the end of the third year
(same for the blind and non-blind group). Throughout
the trial, about 90% of women in the non-treatment
group and 95% in the placebo group did not start hor-
mone therapy.
Because knowing or not knowing that one is taking active
hormone therapy may be important for social and behav-
ioural effects, the results are given separately as well as
combined for the non-blind and blind sub-trials. Differ-
ences between proportions were tested by the Chi-square
test. P-values of less than 0.05 were considered statistically
significant. Women in the HT and no-HT groups (com-
bining blind and non-blind sub-trials) were compared
using age-adjusted logistic regression models. Statistical
analyses were preformed with Intercooled Stata 9.2 (for
contingency tables) and R 2.4.0 – A Language and Envi-
ronment (for logistic regression); no-HT group was used
as the reference.
The women's baseline characteristics were taken from the
recruitment questionnaire, which was carried out on aver-
age 7.0 ± 4.4 months before the women were included
into the trial, Table 1. The women in the HT and non-HT
groups were very similar to each other. However, in the
blind sub-trial the women in the placebo group were
somewhat older, and we have age-adjusted the combined
results.
Years of education were derived from the level: <10 years
include preliminary and basic; 10–11 years) include sec-
ondary and vocational; 12+ years include higher and sci-
entific degrees. Age at menopause was calculated
according to the date of birth and the date of the last men-
strual period as reported in the recruitment questionnaire.
Body mass index (BMI) was calculated as weight in kilo-
grams divided by square of height in meters.
To check the sensitiveness of our questions, we also did a
logistic regression analysis on the age at recruitment. All
outcome variables in which one would expect a decrease
with age (being employed, being retired, psychically or
physically exhausted, lives alone, exercise less frequently,
no partner, no sex partner and other questions on own
sexual activity) did actually show an association.BMC Women's Health 2009, 9:16 http://www.biomedcentral.com/1472-6874/9/16
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Table 1: Description of the background characteristics of the women in the four groups1
Background characteristics Blind sub-trial Non-blind sub-trial
HT Placebo HT Non-treatment
(n) (n = 404) (n = 373) (n = 494) (n = 507)
Age
mean (SD) 58.4 (3.9) 59.0 (3.9) 58.6 (4.0) 58.9 (4.0)
50–54, % 24 20 25 21
55–59, % 39 34 36 35
60+, % 37 46 38 44
Education, years, %2
<10 11 11 10 12
10–11 56 58 56 55
12+ 32 31 35 32
Work status
Employed 68 69 70 67
Retired 29 28 27 30
Other3 333 3
Marital status4
Married 62 60 64 62
Widow 14 16 13 15
Divorced 18 18 17 17
S i n g l e 665 5
Births, mean (SD) 1.9 (1.0) 1.8 (0.9) 1.7 (1.0) 1.7 (1.0)
Age at menopause, mean (SD) 50.3 (3.7) 50.3 (3.9) 50.1 (3.7) 50.5 (3.8)
Height, cm, mean (SD) 164 (5.4) 163 (5.4) 164 (5.1) 164 (5.2)
BMI, kg/m2
mean (SD) 26.9 (4.7) 26.9 (4.2) 27.2 (4.5) 26.9 (4.6)
25–29, % 39 42 39 40
30+, % 22 21 25 21
Current smoker, % 16 14 13 16
1 From the recruitment questionnaire (before inclusion into the trial)
2 No information = 0.2
3 Working at home, unemployed, no information
4 No information: 0.6%BMC Women's Health 2009, 9:16 http://www.biomedcentral.com/1472-6874/9/16
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The study protocol was approved by the Tallinn Commit-
tee of Medical Ethics, Estonia, January 22, 1998, and by
the Research Ethics Committee of University Clinic of
Tampere, Finland, October 12, 1995.
Results
There was no difference between the groups in regard to
proportion of women being employed in the first and
final surveys, Table 2.
In the final survey, the extent of social involvement was
asked with a series of questions on number of friends, par-
ticipation in groups or clubs and contacts with friends and
family. Table 2 gives some examples of the indicators. In
addition to those, the mean and median number of close
friends and number of neighbours visited were calculated.
None of the measures used showed differences between
the groups.
There was no difference between the groups in regard to
marital status (Table 3). There were no statistically signif-
icant differences between the groups in regard to having a
partner or a sex partner.
In the first-year survey, sex and sexual relationships were
the subject of several different questions. The women in
the different groups were relatively similar in regard to
having had sexual intercourse in the past year or being sex-
ually active, Table 4. In the blind sub-trial the other indi-
cators suggested somewhat more sexual inactivity or
disinterest in the placebo group than in the HT-group. In
the non-blind sub-trial, only responses to the question on
sexual activity showed a difference, and even that was sta-
tistically non-significant. In the final survey, the propor-
tions of women who had not had intercourse in the past
year were somewhat higher in the non-HT groups (Table
4, combined analysis). Proportions of women whose part-
ners had sexual difficulties or who were not satisfied with
their partner as a lover were similar in all groups.
In the first-year survey painful intercourse in the past year
was somewhat more common in the placebo and non-
treatment groups than in the HT-groups, both in the blind
sub-trial (5% vs. 8%) and the non-blind sub-trial (6% vs.
8%), but these differences were not statistically signifi-
cant. In the final survey, there was no difference between
the groups.
Weight (calculated as BMI) and the frequency of free-time
exercise were asked in all annual surveys. We use them
here as a proxy of physical activity. In the blind sub-trial,
somewhat more women in the HT-group reported exercis-
ing than in the placebo group, both in the first and the
final survey, Table 5. In the non-blind sub-trial, the find-
ings were the opposite, but the differences between the
groups were small and not statistically significant. Also
the proportion of women in the final survey who reported
being rather often or (almost) always psychically
Table 2: Work and social activity in the four groups
Blind sub-trial Non-blind sub-trial HT vs. no HT1
HT Placebo HT None-treatment OR 95% CI
1st year (n) (n = 306) (n = 271) (n = 364) (n = 382)
Employed2, % 62 62 63 63 0.89 (0.70–1.14)
Retired2, % 30 32 31 31 1.12 (0.86–1.46)
Final survey (n) (n = 319) (n = 301) (n = 398) (n = 428)
Employed3, % 51 57 57 52 0.87 (0.69–1.09)
Retired3, % 37 35 35 37 1.12 (0.87–1.43)
No close friends, % 5.0 5.3 5.5 5.1 0.97 (0.61–1.55)
No neighbors visited, % 6.0 7.0 6.0 9.1 0.73 (0.49–1.10)
Does not belong to any group or club, % 66 65 64 66 0.92 (0.74–1.15)
L i v e s  a l o n e ,  % 1 92 22 1 2 2 0 . 9 2  ( 0 . 7 1 – 1 . 2 1 )
1 Age-adjusted odds ratios (95% confidence intervals), combining the blind and non-blind sub-trial, no-HT group is the reference.
2 No information: 0.76%. The rest were working at home, unemployed or something else.
3 No information: 0.35%.BMC Women's Health 2009, 9:16 http://www.biomedcentral.com/1472-6874/9/16
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exhausted (32–37%) or physically exhausted (33–38%)
were similar.
In the first-year and final survey, body mass index (BMI)
did not vary between the groups, whether it was measured
by proportion of overweight or obese (Table 5) or mean
BMI (data not shown).
The first-year questionnaire included three questions
related to aging, with no difference between the groups in
regard to them, Table 6. In the final survey, women were
asked "do you find it difficult becoming old". In the blind
sub-trial, the proportion of women who said "rather or
very much" was somewhat higher in the placebo group
than the HT-group. In the non-blind sub-trial no differ-
ence between the groups was found.
Discussion and Conclusion
In a trial setting, we found that postmenopausal hormone
therapy had very little impact on employment status,
social involvement or partner relationships. There was a
marginal positive effect on sexual life. Taking into account
our previous results of no effect on the quality of life [21],
the value of HT should be judged on its symptom-reliev-
ing effects and disease effects; the latter have been mainly
negative (see e.g. [22,23]).
However, three methodological reservations should be
considered in regard to our results. First, our indicators
were rough, and some were from questions originally
made to measure other things. Secondly, the response rate
was good for a survey, but still a large proportion of
women did not respond. Thirdly, the exposure was weak
as many women stopped taking their prescribed trial med-
ication.
The two first-mentioned reservations are not likely to be
important. Our analysis by age showed the indicators to
be sensitive to age effects. Even though we do not know
whether the non-respondents were similar in the different
groups, the equal size of the non-respondents suggests so.
The low exposure remains a potential problem, and one
Table 3: Marital status and partner relationships1 in the four groups
Blind sub-trial Non-blind sub-trial HT vs. no HT6
HT, % Placebo, % HT, % None-treatment, % OR (95% CI)
1st year
Marital status2
Married/cohabiting 63 59 63 64 1.01 (0.81–1.27)
Divorced 15 16 16 14 1.04 (0.77–1.41)
Single 8 6 6 6 1.21 (0.77–1.91)
No partner3 34 37 34 34 0.98 (0.78–1.23)
Final year
Marital status4
Married/cohabiting 60 57 61 59 1.06 (0.86–1.31)
Divorced 15 16 17 17 0.95 (0.72–1.26)
Single 7 5 6 5 1.20 (0.77–1.88)
No partner5 34 38 33 37 0.87 (0.70–1.09)
1 For the denominators, See Table 3.
2 The rest were widows (15%) or no information (0.8%).
3 Partner refers to a man you a living with; from the question: "Which kind of views your partner has taken of your participation in this trial?"
4 The rest were widows (18%) or no information (0.1%).
5 From the question: "Are you satisfied with your partner as a friend?"
6 Age-adjusted odds ratios (95% confidence intervals), combining the blind and non-blind arms, no-HT group is the reference.BMC Women's Health 2009, 9:16 http://www.biomedcentral.com/1472-6874/9/16
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could argue that with higher exposure a greater effect
could have been found.
We found no previous trials on the effect of HT on work-
ing status or social relationships. The small improvement
for sexual indicators is in accordance with previous litera-
ture. Available trials suggest that HT, especially oestrogen,
improves genital symptoms and consequently, sexual
functioning (for reviews, see [24,25]). Nevertheless, the
impact on sexual desire is less clear [24,25].
Among many women, loss of interest in sex and low satis-
faction increase after menopause. This was found in this
trial, as well as in previous population-based surveys [26-
29]. Various factors influence sexuality [30]. In this trial,
one third of the women did not have a partner, and others
reported that the partner had sexual problems. But many
women reported sexual problems related to the woman
herself or the relationship. Thus, our results that suggested
a weak positive effect of HT on sexual life are theoretically
interesting, and warrant further studies on HT and sexual-
ity. It would be important to tease out which are due to
physical effects, such as dry vagina – easily corrected with
lubricants – and which are due to psychological effects.
We had two indicators to measure heath behaviour: exer-
cise during free-time and weight/BMI. Our results showed
no impact of HT on these. However, weight and BMI may
reflect metabolic effects rather than behavioural changes.
The effects of HT on weight in previous trials have been
inconsistent, varying from increasing to decreasing weight
and no impact [31,32,24]. According to surveys, some
women discontinue HT because of weight gain that they
believed to be due to HT [14].
Our motive to study these non-medical effects in our trial
was based on lay-beliefs we had faced both in literature
and observed. Our hypothesis before the trial was that the
non-medical effects of HT would be minimal – if any.
Thus we did not systematically study potential biological
pathways. It is likely that proponents of HT for social ben-
efits assume the effects to rise through the increase in gen-
eral well-being as well as through specific hormone
effects, "aestrogen being necessary for a woman to be
Table 4: Sexual life, experiences and views1 in the four groups
Blind sub-trial Non-blind sub-trial HT vs. no HT9
HT, % Placebo, % HT, % None-treatment, % OR (95% CI)
1st year
No intercourse past year2 29 30 27 25 1.11 (0.87–1.42)
Not sexually active3 59 65 52 59 0.82 (0.67–1.00)
Satisfied with sexual relationship4 25 1810 19 21 1.11 (0.85–1.43)
Lost interest in sex5 39 45 41 44 0.91 (0.75–1.12)
Sex not important, in general6 29 2111 28 27 1.17 (0.91–1.50)
Final survey
No intercourse past year2 45 52 47 52 0.77 (0.62–0.95)
Partner has difficulties7 18 17 16 15 1.03 (0.78–1.37)
Not satisfied with partner as a lover8 13 10 11 12 1.24 (0.93–1.65)
1 For the denominators, see Table 3.
2 From the question: "During the past 12 months I have had pains during intercourse"; no information 1.7% (1st year) and 3.3% (final).
3 From the question: "I am satisfied with my current sexual relationship"; includes no information group.
4 From the question: "I am satisfied with my current sexual relationship", definitely; no partner or no information: 58% (WHQ).
5 From the question: "I have lost interest in sexual activity", definitely (WHQ).
6 From the question: "In my age, sexual life is not so important any more", totally agree, (Q49).
7 From the question: "Does your partner experience difficulty in sexual performance?", rather much; no partner or no information: 49%.
8 From the question: "Are you satisfied with your partner as a lover?"; not at all; no partner or no information: 46%.
9 Age-adjusted odds ratios (95% confidence intervals), combining the blind and non-blind arms, non-HT group is the reference.
10 P-value = 0.05.
11 P-value = 0.04.BMC Women's Health 2009, 9:16 http://www.biomedcentral.com/1472-6874/9/16
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whole" (Watkins). Our trial did not support these beliefs.
There was a weak indication of positive effects on sexual-
ity, but the weakness of impact and negative disease
effects of HT are likely to prevent HT being used as a sex-
ual therapy. Further analysis of existing HT trials in regard
to social effects would be welcome.
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Appendix
The key questions (source questionnaire) used in the
study.
￿ Your education? 1. Preliminary, 2. Basic, 3. Secondary,
4. Vocational, 5. Higher, 6. Scientific degree (recruitment)
￿ When was Your last period? Year/month (recruitment)
￿ Your height: _____ cm (recruitment)
￿ Your present weight: _____ kg (recruitment and annual)
Table 5: Physical activity: exercise during free-time and body-mass-index (BMI)1 in the four groups
Blind sub-trial Non-blind sub-trial HT vs. no HT6
HT, % Placebo, % HT, % Placebo, % OR (95% CI)
Exercise
1st year2
Little/none 20 25 25 24 0.88 (0.68–1.14)
(Rather) much 42 347 33 37 1.08 (0.86–1.35)
Final survey3
Little/none 27 358 32 35 0.78 (0.62–0.97)
(Rather) much 33 26 27 30 1.10 (0.88–1.39)
BMI
1st year4
25–29 41 38 39 40 1.01 (0.81–1.27)
≥ 30 23 21 25 23 1.12 (0.86–1.45)
Final survey5
25–29 38 39 39 43 0.91 (0.73–1.13)
≥ 30 24 24 27 22 1.16 (0.91–1.48)
1 For the denominators, see Table 3.
2 No information = 0.45%. The rest answered "some".
3 No information = 1.1%. The rest answered "some".
4 No information = 1.9%.
5 No information = 2.7%.
6 Age-adjusted odds ratios (95% confidence intervals), combining the blind and non-blind arms, non-HT group is the reference.
7 P-value = 0.04.
8 P-value = 0.03.BMC Women's Health 2009, 9:16 http://www.biomedcentral.com/1472-6874/9/16
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￿ Do/did You smoke? 1. No, 2. Yes. I do, 3. Yes, I did ear-
lier (recruitment)
￿ How much have you exercised during your free-time
within past 3 months? 1. Not at all, 2. A little, 3. Some-
what, 4. Rather much, 5. Much (annual)
￿ Are you currently in paid work? 1. No, I am retired, 2.
No, I am unemployed/looking for a job, 3. Yes, I am in
paid work outside home, 4. Yes. I am working at home, 5.
Something else, specify _____ (recruitment, annual)
￿ Who is/are living with you in the same household? (You
may choose more than one alternative) 1. I live alone, 2.
Husband or cohabitant, 3. Child/children, 4. My own par-
ent(s), 5. My husband's/cohabitant's parent(s), 6. Others,
who _____ (first year)
￿ What is your current marital status? 1. Single, 2. Married,
3. Cohabitant, 4. Divorced, 5. Widow (recruitment,
annual)
￿ About how many families in your neighbourhood are
you well enough acquainted with, so that you visit each
other? _____ families (final)
￿ About how many close friends do you have – people you
feel at ease with and can talk with about what is on your
mind? (You may include relatives.) (Enter number on
line) _____ close friends (final)
￿ How active are you in these groups or clubs you belong
to? (If you belong to many, just count those you feel clos-
est to. If you do not belong to any, circle 4.) 1. Very active,
attend most meetings, 2. Fairly active, attend fairly often,
3. Not active, belong to but hardly ever go, 4. Do not
belong to any groups or clubs (final)
￿ Which kind of views has your partner (elukaaslane, the
man you are living with) taken about your participation
in this trial? 1. I do not (currently) have a partner, 2. He
disagrees, 3. He agrees, 4. He does not care, 5. He does not
know, 6. Something else _____ (first year)
￿ Are you satisfied with your partner (elukaaslane) as a
friend? 1. Not at all, 2. A little, 3. Rather much, 4. Very
much, 5. I have no partner (final)
￿ During the past 12 months I have had pains during
intercourse? 1. No, 2. Yes, 3. I have had no intercourse
(first year, final)
￿ I am satisfied with my current sexual relationship
(please omit if not sexual active)? 1. Yes, definitely, 2. Yes,
sometimes, 3. No, not much, 4. No, not at all (WHQ, first
year)
￿ I have lost interest in sexual activity? 1. Yes, definitely, 2.
Yes, sometimes, 3. No, not much, 4. No, not at all (WHQ,
first year)
￿ In my age sexual life is not so important any more? 1. I
do not have a husband/cohabitant, 2. I totally agree, 3. I
somewhat agree, 4. I don't know, 5. I somewhat disagree,
6. I totally disagree (first year)
￿ If you are married or a cohabitant, what is your partner's
age? _____ years (first year)
Table 6: Opinions on own ageing in the four groups
Blind sub-trial Non-blind sub-trial HT vs. no HT5
HT, % Placebo, % HT, % None-treatment, % OR (95% CI)
1st year
Worried about growing old1 8.5 10 9.9 8.1 1.02 (0.70–1.48)
Happy with looks2 28 24 29 28 1.11 (0.87–1.41)
Husband blames climactericum3 35 35 29 32 0.94 (0.74–1.19)
Final year
Becoming old difficult4 18 25 24 21 0.94 (0.73–1.21)
1 From the question: "I worry about growing old", definitely; no information 3.9%, WHQ
2 From the question: "I am happy with the way I look", definitely; no information 3.8%, WHQ.
3 From the question: "My partner thinks my problems are due to climacteric", totally agree; no information 2.0%.
4 From the question: "Do you find it difficult becoming old?" Rather much or very much; no information 1.8%.
5 Age-adjusted odds ratios (95% confidence intervals), combining the blind and non-blind arms, non-HT group is the reference.
6 P-value = 0.02.BMC Women's Health 2009, 9:16 http://www.biomedcentral.com/1472-6874/9/16
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￿ I worry about growing old? 1. Yes, definitely, 2. Yes,
sometimes, 3. No, not much, 4. No, not at all (WHQ, first
year)
￿ I am happy with the way I look? 1. Yes, definitely, 2. Yes,
sometimes, 3. No, not much, 4. No, not at all (WHQ, first
year)
￿ My partner thinks that my problems are due to climac-
teric? 1. I totally agree, 2. I somewhat agree, 3. I don't
know, 4. I somewhat disagree, 5. I totally disagree (first
year)
Do you find it difficult becoming old? 1. Not at all, 2. A
little, 3. Rather much, 4. Very much, 5. I do not know
(final)
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